Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Apr;55(4):315-7.
doi: 10.1136/jcp.55.4.315.

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma

D Gancberg  1 , A Di Leo, G Rouas, T Järvinen, A Verhest, J Isola, M J Piccart, D Larsimont
Affiliations

Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma

D Gancberg et al. J Clin Pathol. 2002 Apr.

Abstract

Aims: Tumour tissue microarray allows the analysis of hundreds of tumour samples simultaneously on a single microscope slide. However, the extremely small tissue samples taken from the original tissue may not always be representative of the entire tumour.

Methods: The reliability of this new technology was investigated by analysing HER-2 oncogene amplification by fluorescence in situ hybridisation (FISH) from representative slides of the whole tumour and small tissue core biopsies from 29 invasive breast tumours.

Results: The tissue microarray method had high accuracy; in only one of 29 cases (3.4%; 95% confidence interval, 0% to 10%) were the results discordant with whole tumour analysis.

Conclusion: Tumour microarray is a highly reliable method for analysing HER-2 oncogene amplification by FISH in human breast tumours.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dual colour fluorescence in situ hybridisation for the HER-2 (red) and α satellite centromeric region of chromosome 17 (green) in paraffin wax embedded breast specimens (DAPI counterstain). Heterogeneity and aneuploidy of invasive tumour cells: two different areas of the same tumour, one with aneuploidy and rare cells showing HER-2 amplification (A), and the other with several cells showing high HER-2 amplification (B).
See this image and copyright information in PMC

Comment in

References

    1. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year follow-up. J Clin Oncol 1992;10:1044–8. - PubMed
    1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48. - PubMed
    1. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 1998;4:844–7. - PubMed
    1. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803–6. - PubMed
    1. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999;154:981–6. - PMC - PubMed

Publication types